Allogene Therapeutics (ALLO) AI Stock Analysis

• Market Cap: $260.29M
• Dividend Yield: N/A
• Average Volume (3M): 2.49M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.88
• Revenue Growth: -100.00%
• EPS Growth: 31.43%
• Country: US
• Employees: 226
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 218,730,800
• 10 Day Avg. Volume: 2,856,244
• 30 Day Avg. Volume: 2,491,258
• PEG Ratio: -0.10
• Price to Book (P/B): 1.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.99
• Enterprise Value/Market Cap: 8.02
• Enterprise Value/Revenue: -47.46K
• Enterprise Value/Gross Profit: -645.86
• Enterprise Value/Ebitda: -2.08
• 1Y Price Target: $8.78
• Price Target Upside: 637.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 43 Neutral
• Price Target: $1.00 ▼(-15.97%Downside)

Allogene Therapeutics is facing substantial financial challenges with persistent losses and reliance on external funding, which significantly impacts its stock score. The technical analysis indicates bearish momentum, and valuation metrics show a lack of profitability. Despite some positive developments from the earnings call regarding clinical trials and cash management, these are not enough to offset the broader financial and operational hurdles.

Positive Factors

Clinical Efficacy

ALLO-316 Phase 1b data at ASCO demonstrates consistent efficacy and safety in a hard-to-treat ccRCC population.

Financial Outlook

Allogene’s strategic cost-realignment efforts prioritize high-impact, value-generating programs, extending the financial runway.

Technological Validation

ALLO-316's results are encouraging and validating of the Dagger technology.

Negative Factors

Clinical Delays

The ALPHA3 update in Large B-cell Lymphoma consolidation is delayed to 1H26 due to site readiness issues.

Market Valuation

ALLO is trading well below cash value, reflecting zero value currently ascribed to the company’s pipeline.

Allogene Therapeutics Business Overview & Revenue Model

Company Description

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

How the Company Makes Money

Allogene Therapeutics makes money primarily through the development and commercialization of its proprietary AlloCAR T cell therapies. The company generates revenue through collaboration agreements, licensing deals, and strategic partnerships with other pharmaceutical companies. These relationships often involve upfront payments, milestone payments based on the achievement of clinical and regulatory goals, and royalties from potential future sales. Additionally, Allogene may engage in funding opportunities such as public offerings or private placements to support its research and development initiatives. The company's success is largely dependent on the progression of its clinical trials and the eventual approval and commercialization of its therapies.

Allogene Therapeutics Financial Statement Overview

Summary

Allogene Therapeutics faces significant financial challenges, with declining revenues, persistent losses, and dependence on external funding. While the balance sheet shows some resilience with cash reserves and moderate leverage, the lack of profitability and cash flow growth indicates the company must address operational inefficiencies to achieve sustainable growth.

Income Statement

Allogene Therapeutics has struggled to generate revenue, with a sharp decline from $38.5M in 2021 to negligible amounts in 2023 and 2024. Consistently negative EBIT and net income reflect ongoing operational challenges. The lack of revenue growth and persistent losses highlight significant financial hurdles.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio, indicating moderate leverage. However, a declining equity base from $1.08B in 2020 to $422M in 2024 signals potential financial strain. The substantial cash reserves provide a buffer, but the shrinking equity ratio raises concerns about long-term stability.

Cash Flow

Negative operating and free cash flows indicate poor cash generation from operations. While financing activities have bolstered cash levels, the reliance on external funding to sustain operations could pose risks. The absence of positive cash flow growth further underscores operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-22.00K	22.00K	95.00K	156.00K	114.09M	0.00
Gross Profit	-3.23M	-192.28M	95.00K	-256.23M	-106.09M	-11.54M
EBITDA	-238.45M	-243.33M	-313.07M	-321.24M	-169.74M	-250.81M
Net Income	-252.32M	-257.59M	-327.26M	-340.41M	-182.05M	-250.22M
Balance Sheet
Total Assets	507.98M	548.71M	642.84M	817.08M	1.04B	1.23B
Cash, Cash Equivalents and Short-Term Investments	280.04M	292.48M	448.70M	576.47M	809.48M	1.03B
Total Debt	81.29M	90.76M	95.12M	95.12M	69.93M	53.78M
Total Liabilities	122.59M	126.53M	130.60M	151.21M	122.23M	148.21M
Stockholders Equity	385.39M	422.18M	512.23M	665.87M	916.41M	1.08B
Cash Flow
Free Cash Flow	-198.12M	-200.99M	-239.25M	-225.71M	-206.26M	-181.05M
Operating Cash Flow	-197.33M	-200.30M	-237.73M	-220.52M	-184.81M	-115.09M
Investing Cash Flow	59.73M	75.69M	163.29M	106.16M	163.66M	-505.12M
Financing Cash Flow	129.01M	116.67M	95.69M	2.95M	11.96M	633.59M

Allogene Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLO, the sentiment is Negative. The current price of 1.19 is below the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.29, and below the 200-day MA of 1.94, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.73 is Neutral, neither overbought nor oversold. The STOCH value of 37.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALLO.

Allogene Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$384.43M	―	-41.31%	―	―	-7.93%
AUTL	53 Neutral	$630.76M	―	-49.91%	―	-14.16%	25.88%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
ALLO	43 Neutral	$260.29M	―	-59.60%	―	-100.00%	31.43%
ZBIO	42 Neutral	$419.60M	―	-115.47%	―	―	―
ANNX	38 Underperform	$317.07M	―	-66.13%	―	―	43.21%
SANA	33 Underperform	$719.52M	―	-71.44%	―	―	19.94%

Allogene Therapeutics Corporate Events

Allogene Therapeutics Holds Annual Stockholder Meeting

On June 18, 2025, Allogene Therapeutics held its Annual Meeting of Stockholders, where key decisions were made. Stockholders elected three Class I Directors to serve until 2028, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent accounting firm for 2025.

The most recent analyst rating on (ALLO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Allogene Therapeutics stock, see the ALLO Stock Forecast page.